| Primary |
| Chemotherapy |
21.6% |
| Prophylaxis |
12.6% |
| Breast Cancer |
11.4% |
| Neutropenia |
11.4% |
| Non-hodgkin's Lymphoma |
7.8% |
| Product Used For Unknown Indication |
6.6% |
| Diffuse Large B-cell Lymphoma |
5.7% |
| Drug Use For Unknown Indication |
3.3% |
| B-cell Lymphoma |
3.0% |
| Chronic Lymphocytic Leukaemia |
2.7% |
| Febrile Neutropenia |
2.7% |
| Primary Effusion Lymphoma |
2.4% |
| Multiple Myeloma |
1.5% |
| Peripheral T-cell Lymphoma Unspecified |
1.5% |
| Acute Myeloid Leukaemia |
1.2% |
| Colorectal Cancer Metastatic |
1.2% |
| Ovarian Cancer |
1.2% |
| Pre-existing Disease |
0.9% |
| Bone Sarcoma |
0.6% |
| Colon Cancer |
0.6% |
|
| Febrile Neutropenia |
32.1% |
| Neutropenia |
16.4% |
| Drug Ineffective |
10.7% |
| Pyrexia |
5.7% |
| Sepsis |
4.3% |
| Septic Shock |
3.6% |
| Thrombocytopenia |
3.6% |
| Infusion Related Reaction |
2.9% |
| Vomiting |
2.9% |
| Dyspnoea |
2.1% |
| Leukopenia |
2.1% |
| Therapeutic Response Decreased |
2.1% |
| Accidental Overdose |
1.4% |
| Back Pain |
1.4% |
| Bone Pain |
1.4% |
| Death |
1.4% |
| Infection |
1.4% |
| Leukocytosis |
1.4% |
| Neck Pain |
1.4% |
| Neutropenic Sepsis |
1.4% |
|
| Secondary |
| Product Used For Unknown Indication |
31.9% |
| Non-hodgkin's Lymphoma |
28.4% |
| Neutropenia |
8.6% |
| Chemotherapy |
5.2% |
| B-cell Lymphoma |
3.4% |
| Breast Cancer |
3.4% |
| Colorectal Cancer Metastatic |
3.4% |
| Lymphoma |
3.4% |
| Chronic Lymphocytic Leukaemia |
2.6% |
| Diffuse Large B-cell Lymphoma |
2.6% |
| Febrile Neutropenia |
2.6% |
| Prophylaxis |
2.6% |
| Rheumatoid Arthritis |
1.7% |
|
| Cerebral Infarction |
16.0% |
| Death |
16.0% |
| Febrile Neutropenia |
12.0% |
| Arthrodesis |
8.0% |
| Leukopenia |
8.0% |
| Neutropenia |
8.0% |
| Bone Pain |
4.0% |
| Cellulitis |
4.0% |
| Cerebrovascular Accident |
4.0% |
| Fat Tissue Increased |
4.0% |
| Infection |
4.0% |
| Paraesthesia |
4.0% |
| Pneumonia |
4.0% |
| Pyrexia |
4.0% |
|
| Concomitant |
| Diffuse Large B-cell Lymphoma |
16.1% |
| Prophylaxis |
14.3% |
| Mantle Cell Lymphoma |
13.4% |
| Premedication |
8.9% |
| Product Used For Unknown Indication |
8.0% |
| Chemotherapy |
5.4% |
| Metastatic Gastric Cancer |
5.4% |
| Non-hodgkin's Lymphoma |
4.5% |
| Diabetes Mellitus |
3.6% |
| Primary Effusion Lymphoma |
3.6% |
| Infection |
2.7% |
| Tumour Lysis Syndrome |
2.7% |
| Lung Carcinoma Cell Type Unspecified Stage Iv |
1.8% |
| Lung Neoplasm Malignant |
1.8% |
| Lung Squamous Cell Carcinoma Stage Unspecified |
1.8% |
| Neutropenia |
1.8% |
| Pain |
1.8% |
| Breast Cancer |
0.9% |
| Gastritis Prophylaxis |
0.9% |
| Insomnia |
0.9% |
|
| Febrile Neutropenia |
23.5% |
| Thrombocytopenia |
11.8% |
| Dizziness |
5.9% |
| Gastrointestinal Haemorrhage |
5.9% |
| Hepatic Enzyme Increased |
5.9% |
| Infection |
5.9% |
| Nausea |
5.9% |
| Oesophagitis |
5.9% |
| Pyrexia |
5.9% |
| Respiratory Failure |
5.9% |
| Vomiting |
5.9% |
| Wheezing |
5.9% |
| White Blood Cell Count Increased |
5.9% |
|
